Entrar/Registro  
HOME SPANISH
 
Gaceta Médica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Gaceta Médica de México >Year 2008, Issue 6


Ibáñez-Hernández MG, Macías-Islas MA, Zavalza-Gómez AB, Pacheco-Moisés FP , Ortiz GG
Efecto del ibuprofeno y ácido acetilsalicílico sobre el deterioro cognitivo, poder antioxidante total e isoprostanos séricos
Gac Med Mex 2008; 144 (6)

Language: Español
References: 37
Page: 497-502
PDF: 77.62 Kb.

[Full text - PDF]

ABSTRACT

Background: There is controversy about the prevention of Alzheimer’s disease with nonsteroidal antiinflammatory drugs (NSAIDs). Our objective was to evaluate the effect of ibuprofen and acetylsalicylic acid on cognitive impairment, serum total antioxidant power (TAP) and isoprostane (8-iso-PGF2á). Methods: We applied from April 2004 to February 2006 a Folstein mini-mental state (MMSE), Syndrome Kurtz Test (SKT) and a geriatric depression scale (Yasevage) to eighteen eligible women. They were 55 years and older. All women (n=18) with normal cognitive state were randomized to ibuprofen 400 mg per day (n=9) and acetylsalicylic acid 500 mg per day (n=9) for one year. Serum TAP and 8-iso-PGF2á were performed at baseline, after six months and one year of treatment. Results: After one year of treatment with acetylsalicylic acid five women (55.6%) raised their score 4 points in MMSE compared with 3 points increased (33.3%) showed by the ibuprofen group. TAP increased (p=0.01) and 8-iso-PGF2á reduced (p=0.01) in both groups compared with baseline. Conclusions: Both drugs improved the cognitive state and oxidative status of our population.


Key words: Acetylsalicylic acid, cognitive impairment, ibuprofen, isoprostane, serum total antioxidant power.


REFERENCES

  1. Folstein MF, Folstein SE, McHugh PR. Minimental state: A practical guide for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.

  2. Mohr E. Diseño de ensayos clínicos en la época de los tratamientos de la demencia: dificultades y opciones. En: Gauthier S, Scheltens P, Cummings JL, editores. Enfermedad de Alzheimer y trastornos relacionados. Barcelona, España: Ars Medica; 2006. pp. 119-120.

  3. Fernández S. Evaluación neuropsicológica de las demencias. En: Arango JC, Fernández S, Ardila A, editores. Las demencias. Aspectos clínicos, neuropsicológicos y tratamiento. México: El Manual Moderno; 2003. p. 143.

  4. Grundman M, Petersen RC, Ferris SH. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004;61:59-66.

  5. Greenaway MC, Lacritz LH, Binegar D. Patterns of verbal memory performance in mild cognitive impairment, Alzheimer disease, and normal aging. Cog Behav Neurol 2006;19:79-84.

  6. Kryscio RJ, Schmitt FA, Salazar JC. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 2006;66:828-832.

  7. Small GW. What we need to know about age related memory loss. BMJ 2002;324:1502-1505.

  8. Ardila A. El proceso de envejecimiento normal. En: Arango JC, Fernández S, Ardila A, editores. Las demencias. Aspectos clínicos, neuropsicológicos y tratamiento. México: El Manual Moderno; 2003. pp. 3-7.

  9. Ostrosky F. Determination of normative criteria and validation of the SKT for its use in spanish population. J Int Psychogeriatr 1999:2-11.

  10. Aguado C. Adaptación y validación al castellano de la versión abreviada de la Geriatric Depresión Scale (GDS) de Yesavage. Aten Primaria 2000; 26(Supl 1):328.

  11. Nunomura A, Castellani RJ, Zhu X. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65(7):631-641.

  12. Head E, Liu J, Hagen M. Oxidative damage increases with age in a canine model of human brain aging. J Neurochem 2002;82:375-381.

  13. Dorado C, Rugeiro C, Rivas S. Estrés oxidativo y neurodegeneración. Rev Fac Med UNAM 2003;46(6):229-235.

  14. Montine TJ, Beal MF, Cudkowicz ME. Increased CSF F2 – isoprostane concentration in probable AD. Neurology 1999;52(3):562-565.

  15. Mark RJ, Fuson KS, May PC. Characterization of 8-epiprostaglandin FF2( alpha) as a marker of amyloid [beta]-peptide-induced oxidative damage. J Neurochem 1999;72(3):1146-1153.

  16. Veld BA, Ruitenberg A, Hofman A. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001;345:1515-1521.

  17. Broe GA, Grayson DA, Creasey HM. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000;57:1586-1591.

  18. Kang JH, Grodstein F. Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. Neurology 2003;60:1591-1597.

  19. Crean AJ, Gussekloo J, Vrijsen B. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol 2005;161:114-120.

  20. Jantzen PT, Connor KE, DiCarlo G. Microglial activation and –amyloid deposits reduction caused by nitric oxide- releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;(6):2246-2254.

  21. McGeer PL, Schuzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: A review of 17 epidemiologic studies. Neurology 1996;47(2):425-432.

  22. Reines SA. Block GA, Morris JC. Rofecoxib No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.

  23. Halliday GM, Shepherd CE, McCann HD. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 2000; 57(6):831-836.

  24. Eriksen JL, Sagi SA, Smith TE. NSAIDs and enatiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J Clin Invest 2003;112:440-449.

  25. Sugaya K, Uz T, Kumar V. New anti-inflammatory treatment strategy in Alzheimer’s disease. Jpn J Pharmacol 2000;82:85-94.

  26. Bradbury J. New mechanism proposed for NSAIDs reduction of Alzheimer’s disease incidence. Lancet 2001;358:1616.

  27. Broe GA, Grayson DA, Creasey HM. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000;57(11):1586-1591.

  28. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:128-131.

  29. Oxford Biomedical Research. Enzyme immunoassay for isoprostane. Product No. EA 84.

  30. Oxford Biomedical Research. Colorimetric microplate assay for total antioxidant power. Product No. TA 01.

  31. Cockrell JR, Folstein MF. Minimental state examination (MMSE). Psychopharmacol Bull 1988;24:689-692.

  32. Lim GP, Yang F, Chu T. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 2000;20(15):5709- 5714.

  33. Sung JJY, Russell RI, Yeomans N, Chan FKL, Chen SL, Fock KM. Nonsteroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol 2000;(Suppl):G58-G68.

  34. Aalami OO, Fang TD, Song HM, Nacamuli RP. Physiological features of aging persons. Arch Surg 2003;(138):1068-1076.

  35. Russell RI. Non-steroidal anti-inflammatory drugs and gastrointestinal damage –problems and solutions. Postgraduate Med J 2001;77(904):82-88.

  36. Huerta C, Varas-Lorenzo C, Castellsague J, Rodríguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006;92(11):1610-1615.

  37. Insel PA. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. En: Goodman & Gilman’s. The pharmacological basis of therapeutics. 8th edition. Republic of Singapure: Maxwell Macmillan International Editions; 1991. pp. 638-681.






>Journals >Gaceta Médica de México >Year 2008, Issue 6
 

· Journal Index 
· Links 
       
Copyright 2010